Research Shows Merck & Co.’s Keytruda Cut Risk Of Death In Lung Cancer Patients By 51 Percent

New research shows a prescription cancer drug combined with chemotherapy cut the risk of death in non-small-cell lung cancer patients by 51 percent, Forbes reports. The study published Monday morning, explains how a combination of platinum chemotherapy and ...